Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR 40.45
+0.29 (0.71%)
Nov 7, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $12.22B USD in the quarter ending September 30, 2025, with 2.77% growth. This brings the company's revenue in the last twelve months to $48.03B, up 1.26% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$48.03B
Revenue Growth
+1.26%
P/S Ratio
2.01
Revenue / Employee
$1.41M
Employees
34,100
Market Cap
82.08B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Bristol-Myers Squibb Company News
- 3 days ago - JPMorgan Chase & Co. Acquires Significant Stake in Bristol-Myers Squibb Co. - GuruFocus
- 3 days ago - Bristol Myers (BMY) Agrees to $239 Million Settlement Over Celgene Claims - GuruFocus
- 5 days ago - Bristol-Myers Squibb: Way Too Cheap At 7x P/E - Seeking Alpha
- 6 days ago - Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth - Seeking Alpha
- 6 days ago - BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - Benzinga
- 6 days ago - Bristol-Myers Squibb (BMY) Announces $7 Billion Cash Tender Offers - GuruFocus
- 6 days ago - Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Wallstreet:Online
- 6 days ago - Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - Wallstreet:Online